Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;98(5):670-677.
doi: 10.1111/cen.14884. Epub 2023 Feb 6.

Height benefit of GnRH agonists after age 8 in a Portuguese cohort of central precocious puberty

Carolina Castro  1 , Filipa Espada  1   2 , Ana Luísa Leite  3 , Ana Antunes  4 , Brígida Robalo  5   6 , Daniela Amaral  7 , Elisa Galo  8 , Sofia Castro  9 , Sofia Ferreira  10 , Catarina Limbert  11   12
Affiliations

Height benefit of GnRH agonists after age 8 in a Portuguese cohort of central precocious puberty

Carolina Castro et al. Clin Endocrinol (Oxf). 2023 May.

Abstract

Objective: Idiopathic central precocious puberty (iCPP) is common in paediatric endocrinology. Gonadotropin-releasing hormone agonists (GnRHa) are safe, but the effect on final height and the ideal timing for treatment remains controversial. This study aims to assess the effectiveness of GnRHa on growth outcomes in girls with iCPP treated before and after the age of 8 years old.

Design and patients: This retrospective longitudinal study evaluated data from Portuguese girls with iCPP who completed treatment between 2010 and 2021.

Measurements: Auxological and clinical characteristics were compared according to age at treatment onset.

Results: A cohort of 134 girls with iCPP, was divided into early treatment (ET) (<8 years, n = 48) and later treatment (LT) groups (≥8 years, n = 86). In both groups, most children presented with Tanner II and III. Tanner IV was more frequent in LT group (p = .003). At the end of treatment, predicted adult height increased in both groups (ET p = .032; LT p = .04) and bone age significantly slowed down in all participants (p = .008, p = .034). The height gain was greater in the ET group, but without significant differences (p = .065).

Conclusions: Treatment with GnRHa improved final height in all girls with iCPP, even when initiated after 8 years. To achieve better outcomes, treatment should be provided promptly after diagnosis.

Keywords: GnRH agonists; final adult height; growth improvement; idiopathic central precocious puberty; target height.

PubMed Disclaimer

References

REFERENCES

    1. Cheuiche AV, da Silveira LG, de Paula LCP, Lucena IRS, Silveiro SP. Diagnosis and management of precocious sexual maturation: an updated review. Eur J Pediatr. 2021;180(10):3073-3087.
    1. Bräuner Ev, Busch AS, Eckert-Lind C, Koch T, Hickey M, Juul A. Trends in the incidence of central precocious puberty and normal variant puberty among children in Denmark, 1998 to 2017. JAMA Network Open. 2020;3(10):e2015665.
    1. Carel JC, Léger J. Precocious puberty. N Engl J Med. 2008;358(22):2366-2377.
    1. Latronico AC, Brito VN, Carel JC. Causes, diagnosis, and treatment of central precocious puberty. Lancet Diabetes Endocrinol. 2016;4(3):265-274.
    1. Jung MK, Song KC, Kwon AR, Chae HW, Kim DH, Kim HS. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone agonist with or without growth hormone. Ann Pediatr Endocrinol Metab. 2014;19(4):214-219.

Publication types

Substances

LinkOut - more resources